Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
What it means
- What to watch: Good results are the headline, guidance is the sequel — and markets usually care more about the sequel.
- How the stock is trading: $MRK +2.40% in the latest session.
- Timing: It landed before the opening bell — early risers had it with their coffee, and the next session was the first that could react.
Where the stock stands
$MRK last traded at $144.31, +2.40% on the session. That puts it 8.0% shy of its 52-week high of $156.92 and 76% clear of its low of $82.01 — in the upper part of the range. Over the year it has ranged 91% from low to high: a wide band — moves of several percent in a week come with the territory. These are latest-session quotes, not live prices — the live tape is on the $MRK page.
How much coverage it is getting
Wook has logged 12 stories on $MRK in the last 30 days, 7 of them this week. At its 30-day pace you would expect about 3 a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories the wording ran 8% bullish, 50% neutral and 42% bearish. This one reads bullish, so it sits in a small minority — the contrarian in the room. 3 came from CNBC and the rest from other outlets — broad coverage, not one desk talking to itself. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Earnings stories turn less on the headline numbers than on how they compare with what analysts expected, and on guidance for next quarter. A beat with weak guidance can land worse than a miss with a raised outlook — markets grade on the curve. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$MRK earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $MRK page has the full chart, the filings and the valuation model behind every figure here. Want the facts without the spin? Read how two or three outlets frame the same story — where they agree is the news, where they differ is the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $MRK is from its high, or how this week's coverage compares.
How this analysis was made
CNBC published it, and Wook filed it under Earnings. It reads bullish at medium severity because of “profit” in the wording, with nothing on the bearish side to offset it. It was matched to $MRK. The preview above is the publisher's own wording.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
CNBC published this on October 29, 2026. $MRK has moved -0.46% ($144.97 to $144.31). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.